Correlation Between Zentalis Pharmaceuticals and OS Therapies

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Zentalis Pharmaceuticals and OS Therapies at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Zentalis Pharmaceuticals and OS Therapies into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Zentalis Pharmaceuticals Llc and OS Therapies Incorporated, you can compare the effects of market volatilities on Zentalis Pharmaceuticals and OS Therapies and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Zentalis Pharmaceuticals with a short position of OS Therapies. Check out your portfolio center. Please also check ongoing floating volatility patterns of Zentalis Pharmaceuticals and OS Therapies.

Diversification Opportunities for Zentalis Pharmaceuticals and OS Therapies

0.07
  Correlation Coefficient

Significant diversification

The 3 months correlation between Zentalis and OSTX is 0.07. Overlapping area represents the amount of risk that can be diversified away by holding Zentalis Pharmaceuticals Llc and OS Therapies Incorporated in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on OS Therapies and Zentalis Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Zentalis Pharmaceuticals Llc are associated (or correlated) with OS Therapies. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of OS Therapies has no effect on the direction of Zentalis Pharmaceuticals i.e., Zentalis Pharmaceuticals and OS Therapies go up and down completely randomly.

Pair Corralation between Zentalis Pharmaceuticals and OS Therapies

Given the investment horizon of 90 days Zentalis Pharmaceuticals Llc is expected to under-perform the OS Therapies. But the stock apears to be less risky and, when comparing its historical volatility, Zentalis Pharmaceuticals Llc is 1.63 times less risky than OS Therapies. The stock trades about -0.05 of its potential returns per unit of risk. The OS Therapies Incorporated is currently generating about 0.02 of returns per unit of risk over similar time horizon. If you would invest  352.00  in OS Therapies Incorporated on September 18, 2024 and sell it today you would lose (50.00) from holding OS Therapies Incorporated or give up 14.2% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthInsignificant
Accuracy100.0%
ValuesDaily Returns

Zentalis Pharmaceuticals Llc  vs.  OS Therapies Incorporated

 Performance 
       Timeline  
Zentalis Pharmaceuticals 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Zentalis Pharmaceuticals Llc has generated negative risk-adjusted returns adding no value to investors with long positions. Despite inconsistent performance in the last few months, the Stock's basic indicators remain quite persistent which may send shares a bit higher in January 2025. The latest mess may also be a sign of long-standing up-swing for the company institutional investors.
OS Therapies 

Risk-Adjusted Performance

1 of 100

 
Weak
 
Strong
Insignificant
Compared to the overall equity markets, risk-adjusted returns on investments in OS Therapies Incorporated are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. In spite of fairly weak basic indicators, OS Therapies may actually be approaching a critical reversion point that can send shares even higher in January 2025.

Zentalis Pharmaceuticals and OS Therapies Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Zentalis Pharmaceuticals and OS Therapies

The main advantage of trading using opposite Zentalis Pharmaceuticals and OS Therapies positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Zentalis Pharmaceuticals position performs unexpectedly, OS Therapies can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in OS Therapies will offset losses from the drop in OS Therapies' long position.
The idea behind Zentalis Pharmaceuticals Llc and OS Therapies Incorporated pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..

Other Complementary Tools

Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Money Managers
Screen money managers from public funds and ETFs managed around the world